SG11201503658XA - Protein slurp-1 for use in the treatment of ocular diseases - Google Patents
Protein slurp-1 for use in the treatment of ocular diseasesInfo
- Publication number
- SG11201503658XA SG11201503658XA SG11201503658XA SG11201503658XA SG11201503658XA SG 11201503658X A SG11201503658X A SG 11201503658XA SG 11201503658X A SG11201503658X A SG 11201503658XA SG 11201503658X A SG11201503658X A SG 11201503658XA SG 11201503658X A SG11201503658X A SG 11201503658XA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- ocular diseases
- slurp
- protein
- protein slurp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- Marine Sciences & Fisheries (AREA)
- Cell Biology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12196007.4A EP2740485B1 (fr) | 2012-12-07 | 2012-12-07 | Protéine slurp-1 pour l'utilisation dans le traitement des maladies oculaires |
| PCT/EP2013/075981 WO2014087022A1 (fr) | 2012-12-07 | 2013-12-09 | Protéine slurp-1 destinée à être utilisée dans le traitement de maladies oculaires |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201503658XA true SG11201503658XA (en) | 2015-06-29 |
Family
ID=47297008
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201503658XA SG11201503658XA (en) | 2012-12-07 | 2013-12-09 | Protein slurp-1 for use in the treatment of ocular diseases |
| SG10201705592YA SG10201705592YA (en) | 2012-12-07 | 2013-12-09 | Protein slurp-1 for use in the treatment of ocular diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201705592YA SG10201705592YA (en) | 2012-12-07 | 2013-12-09 | Protein slurp-1 for use in the treatment of ocular diseases |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10098925B2 (fr) |
| EP (1) | EP2740485B1 (fr) |
| JP (1) | JP6335188B2 (fr) |
| KR (1) | KR20150108351A (fr) |
| CN (1) | CN105188731B (fr) |
| AU (1) | AU2013353957B2 (fr) |
| BR (1) | BR112015013215A2 (fr) |
| CA (1) | CA2891201A1 (fr) |
| CL (1) | CL2015001520A1 (fr) |
| EA (1) | EA201591095A1 (fr) |
| IL (1) | IL239078A0 (fr) |
| MX (1) | MX2015006779A (fr) |
| SG (2) | SG11201503658XA (fr) |
| WO (1) | WO2014087022A1 (fr) |
| ZA (1) | ZA201503747B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2740485B1 (fr) * | 2012-12-07 | 2018-10-31 | Brightpulse Holding LTD. | Protéine slurp-1 pour l'utilisation dans le traitement des maladies oculaires |
| EP3689327A1 (fr) * | 2019-01-24 | 2020-08-05 | Organes Tissus Régénération Réparation Remplacement | Composition pharmaceutique dans le traitement de lésions pulmonaires |
| CN114601915B (zh) * | 2022-03-25 | 2023-04-07 | 四川大学华西医院 | Slurp1蛋白在制备预防或治疗皮肤弹性纤维疾病的药物中的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1257184B (it) | 1992-12-22 | 1996-01-10 | Applied Research Systems | Preparato ad attivita' antinfiammatoria, anticoagulante e antitumorale |
| US7135454B2 (en) * | 2003-04-16 | 2006-11-14 | Applied Research Systems Ars Holding N.V. | Use of SLURP-1 compositions for treating schizophrenia |
| US20100303788A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases |
| CA2806143A1 (fr) * | 2010-07-30 | 2012-02-02 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mb H | Dispositifs d'administration de medicaments et formulations de facteur de croissance pour accelerer la cicatrisation de plaies |
| EP3345627B1 (fr) * | 2011-06-03 | 2021-01-06 | Ophidion Inc. | Compositions et procédés de transport à travers la barrière hémato-encéphalique |
| US9132193B2 (en) * | 2012-11-05 | 2015-09-15 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of Slurp1 as an imunomodulatory molecule in the ocular surface |
| JP6254529B2 (ja) * | 2012-11-08 | 2017-12-27 | 国立大学法人山口大学 | 角結膜障害の治療剤 |
| EP2740485B1 (fr) * | 2012-12-07 | 2018-10-31 | Brightpulse Holding LTD. | Protéine slurp-1 pour l'utilisation dans le traitement des maladies oculaires |
-
2012
- 2012-12-07 EP EP12196007.4A patent/EP2740485B1/fr not_active Not-in-force
-
2013
- 2013-12-09 MX MX2015006779A patent/MX2015006779A/es unknown
- 2013-12-09 SG SG11201503658XA patent/SG11201503658XA/en unknown
- 2013-12-09 BR BR112015013215A patent/BR112015013215A2/pt not_active IP Right Cessation
- 2013-12-09 EA EA201591095A patent/EA201591095A1/ru unknown
- 2013-12-09 SG SG10201705592YA patent/SG10201705592YA/en unknown
- 2013-12-09 WO PCT/EP2013/075981 patent/WO2014087022A1/fr active Application Filing
- 2013-12-09 KR KR1020157015595A patent/KR20150108351A/ko not_active Application Discontinuation
- 2013-12-09 US US14/650,277 patent/US10098925B2/en not_active Expired - Fee Related
- 2013-12-09 CA CA2891201A patent/CA2891201A1/fr not_active Abandoned
- 2013-12-09 JP JP2015546050A patent/JP6335188B2/ja not_active Expired - Fee Related
- 2013-12-09 CN CN201380064175.2A patent/CN105188731B/zh not_active Expired - Fee Related
- 2013-12-09 AU AU2013353957A patent/AU2013353957B2/en not_active Ceased
-
2015
- 2015-05-26 ZA ZA2015/03747A patent/ZA201503747B/en unknown
- 2015-05-28 IL IL239078A patent/IL239078A0/en unknown
- 2015-06-04 CL CL2015001520A patent/CL2015001520A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016502558A (ja) | 2016-01-28 |
| CL2015001520A1 (es) | 2016-05-20 |
| SG10201705592YA (en) | 2017-08-30 |
| ZA201503747B (en) | 2016-03-30 |
| CN105188731A (zh) | 2015-12-23 |
| IL239078A0 (en) | 2015-07-30 |
| EA201591095A1 (ru) | 2015-11-30 |
| US10098925B2 (en) | 2018-10-16 |
| CA2891201A1 (fr) | 2014-06-12 |
| US20150320831A1 (en) | 2015-11-12 |
| WO2014087022A1 (fr) | 2014-06-12 |
| JP6335188B2 (ja) | 2018-05-30 |
| AU2013353957A1 (en) | 2015-05-28 |
| EP2740485A1 (fr) | 2014-06-11 |
| KR20150108351A (ko) | 2015-09-25 |
| MX2015006779A (es) | 2015-10-29 |
| AU2013353957B2 (en) | 2018-05-17 |
| EP2740485B1 (fr) | 2018-10-31 |
| CN105188731B (zh) | 2019-02-05 |
| BR112015013215A2 (pt) | 2018-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2300008I1 (hu) | Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében | |
| HK1209195A1 (en) | Contact lens use in the treatment of an ophthalmologic condition | |
| HK1213192A1 (zh) | 用於在人類受試者中治療眼部疾病的方法和裝置 | |
| HK1203478A1 (en) | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | |
| HK1222552A1 (zh) | 索布替羅用於治療髓鞘形成疾病 | |
| GB2492487B (en) | Cannabinoids for use in the treatment of neurodegenerative diseases or disorders | |
| HK1210968A1 (en) | Compositions and treatment for eye diseases and disorders | |
| AP2014007533A0 (en) | Substituted benzylindazoles for use as BUB1 kinaseinhibitors in the treatment of hyperproliferative diseases | |
| IL239368A0 (en) | Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system | |
| IL229474A0 (en) | Cannabinoids for use in the treatment of neuropathic pain | |
| EP2906295A4 (fr) | Méthodes de traitement de maladies oculaires | |
| ZA201500547B (en) | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases | |
| HK1206344A1 (en) | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases bace1 ---- | |
| EP2709632A4 (fr) | Compositions et procédés pour le traitement de maladies de la peau | |
| ITRM20120530A1 (it) | Compounds for use in the treatment of parasitic diseases | |
| IL239078A0 (en) | Protein for use in the treatment of eye diseases | |
| IL231115A0 (en) | Peptides for use in the treatment of diseases and disorders related to - 1 - il | |
| GB201306413D0 (en) | The local treatment of ophthalmic diseases |